178 related articles for article (PubMed ID: 18928705)
1. [Congenital disorder of glycosylation type 1b. Experience with mannose treatment].
Martín Hernández E; Vega Pajares AI; Pérez González B; Ecay Crespo MJ; Leal Pérez F; Manzanares López-Manzanares J; Ugarte Pérez M; Pérez-Cerdá Silvestre C
An Pediatr (Barc); 2008 Oct; 69(4):358-65. PubMed ID: 18928705
[TBL] [Abstract][Full Text] [Related]
2. The clinical spectrum of phosphomannose isomerase deficiency, with an evaluation of mannose treatment for CDG-Ib.
de Lonlay P; Seta N
Biochim Biophys Acta; 2009 Sep; 1792(9):841-3. PubMed ID: 19101627
[TBL] [Abstract][Full Text] [Related]
3. Oral mannose therapy persistently corrects the severe clinical symptoms and biochemical abnormalities of phosphomannose isomerase deficiency.
Harms HK; Zimmer KP; Kurnik K; Bertele-Harms RM; Weidinger S; Reiter K
Acta Paediatr; 2002; 91(10):1065-72. PubMed ID: 12434892
[TBL] [Abstract][Full Text] [Related]
4. Genetic and metabolic analysis of the first adult with congenital disorder of glycosylation type Ib: long-term outcome and effects of mannose supplementation.
Westphal V; Kjaergaard S; Davis JA; Peterson SM; Skovby F; Freeze HH
Mol Genet Metab; 2001 May; 73(1):77-85. PubMed ID: 11350186
[TBL] [Abstract][Full Text] [Related]
5. Mannose treatment improves immune deficiency in mannose phosphate isomerase-congenital disorder of glycosylation: case report and review of literature.
De Graef D; Mousa J; Waberski MB; Morava E
Ther Adv Rare Dis; 2022; 3():26330040221091283. PubMed ID: 37180423
[TBL] [Abstract][Full Text] [Related]
6. Asymptomatic phosphomannose isomerase deficiency (MPI-CDG) initially mistaken for excessive alcohol consumption.
Helander A; Jaeken J; Matthijs G; Eggertsen G
Clin Chim Acta; 2014 Apr; 431():15-8. PubMed ID: 24508628
[TBL] [Abstract][Full Text] [Related]
7. Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy.
Niehues R; Hasilik M; Alton G; Körner C; Schiebe-Sukumar M; Koch HG; Zimmer KP; Wu R; Harms E; Reiter K; von Figura K; Freeze HH; Harms HK; Marquardt T
J Clin Invest; 1998 Apr; 101(7):1414-20. PubMed ID: 9525984
[TBL] [Abstract][Full Text] [Related]
8. Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts.
Sharma V; Ichikawa M; He P; Scott DA; Bravo Y; Dahl R; Ng BG; Cosford ND; Freeze HH
J Biol Chem; 2011 Nov; 286(45):39431-8. PubMed ID: 21949237
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal and other clinical manifestations in 17 children with congenital disorders of glycosylation type Ia, Ib, and Ic.
Damen G; de Klerk H; Huijmans J; den Hollander J; Sinaasappel M
J Pediatr Gastroenterol Nutr; 2004 Mar; 38(3):282-7. PubMed ID: 15076627
[TBL] [Abstract][Full Text] [Related]
10. Genomic organization of the human phosphomannose isomerase (MPI) gene and mutation analysis in patients with congenital disorders of glycosylation type Ib (CDG-Ib).
Schollen E; Dorland L; de Koning TJ; Van Diggelen OP; Huijmans JG; Marquardt T; Babovic-Vuksanovic D; Patterson M; Imtiaz F; Winchester B; Adamowicz M; Pronicka E; Freeze H; Matthijs G
Hum Mutat; 2000 Sep; 16(3):247-52. PubMed ID: 10980531
[TBL] [Abstract][Full Text] [Related]
11. Komrower Lecture. Congenital disorders of glycosylation (CDG): it's all in it!
Jaeken J
J Inherit Metab Dis; 2003; 26(2-3):99-118. PubMed ID: 12889654
[TBL] [Abstract][Full Text] [Related]
12. Successful liver transplantation and long-term follow-up in a patient with MPI-CDG.
Janssen MC; de Kleine RH; van den Berg AP; Heijdra Y; van Scherpenzeel M; Lefeber DJ; Morava E
Pediatrics; 2014 Jul; 134(1):e279-83. PubMed ID: 24982104
[TBL] [Abstract][Full Text] [Related]
13. A zebrafish model of congenital disorders of glycosylation with phosphomannose isomerase deficiency reveals an early opportunity for corrective mannose supplementation.
Chu J; Mir A; Gao N; Rosa S; Monson C; Sharma V; Steet R; Freeze HH; Lehrman MA; Sadler KC
Dis Model Mech; 2013 Jan; 6(1):95-105. PubMed ID: 22899857
[TBL] [Abstract][Full Text] [Related]
14. Mannose supplementation corrects GDP-mannose deficiency in cultured fibroblasts from some patients with Congenital Disorders of Glycosylation (CDG).
Rush JS; Panneerselvam K; Waechter CJ; Freeze HH
Glycobiology; 2000 Aug; 10(8):829-35. PubMed ID: 10929009
[TBL] [Abstract][Full Text] [Related]
15. Seizures and stupor during intravenous mannose therapy in a patient with CDG syndrome type 1b (MPI-CDG).
Schroeder AS; Kappler M; Bonfert M; Borggraefe I; Schoen C; Reiter K
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S497-502. PubMed ID: 21240668
[TBL] [Abstract][Full Text] [Related]
16. Long term outcome of MPI-CDG patients on D-mannose therapy.
Girard M; Douillard C; Debray D; Lacaille F; Schiff M; Vuillaumier-Barrot S; Dupré T; Fabre M; Damaj L; Kuster A; Torre S; Mention K; McLin V; Dobbelaere D; Borgel D; Bauchard E; Seta N; Bruneel A; De Lonlay P
J Inherit Metab Dis; 2020 Nov; 43(6):1360-1369. PubMed ID: 33098580
[TBL] [Abstract][Full Text] [Related]
17. Recurrent thrombo-embolism in a child with a congenital disorder of glycosylation (CDG) type Ib and treatment with mannose.
Tamminga RY; Lefeber DJ; Kamps WA; van Spronsen FJ
Pediatr Hematol Oncol; 2008 Dec; 25(8):762-8. PubMed ID: 19065443
[TBL] [Abstract][Full Text] [Related]
18. A broad spectrum of clinical presentations in congenital disorders of glycosylation I: a series of 26 cases.
de Lonlay P; Seta N; Barrot S; Chabrol B; Drouin V; Gabriel BM; Journel H; Kretz M; Laurent J; Le Merrer M; Leroy A; Pedespan D; Sarda P; Villeneuve N; Schmitz J; van Schaftingen E; Matthijs G; Jaeken J; Korner C; Munnich A; Saudubray JM; Cormier-Daire V
J Med Genet; 2001 Jan; 38(1):14-9. PubMed ID: 11134235
[TBL] [Abstract][Full Text] [Related]
19. A novel disorder of N-glycosylation due to phosphomannose isomerase deficiency.
de Koning TJ; Dorland L; van Diggelen OP; Boonman AM; de Jong GJ; van Noort WL; De Schryver J; Duran M; van den Berg IE; Gerwig GJ; Berger R; Poll-The BT
Biochem Biophys Res Commun; 1998 Apr; 245(1):38-42. PubMed ID: 9535779
[TBL] [Abstract][Full Text] [Related]
20. Ablation of mouse phosphomannose isomerase (Mpi) causes mannose 6-phosphate accumulation, toxicity, and embryonic lethality.
DeRossi C; Bode L; Eklund EA; Zhang F; Davis JA; Westphal V; Wang L; Borowsky AD; Freeze HH
J Biol Chem; 2006 Mar; 281(9):5916-27. PubMed ID: 16339137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
